Targeted therapies for treating active psoriatic arthritis in adults

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study evaluates the efficacy and safety of targeted therapies for adults with active psoriatic arthritis (PsA). Participants will be randomized into three treatment arms: lutikizumab monotherapy, risankizumab monotherapy, or a combination of both therapies. The study aims to assess changes in disease symptoms and will enroll approximately 120 participants across 40 sites worldwide. Participants will undergo regular visits and procedures throughout the trial.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Participant is willing and able to comply with procedures required in the Master Protocol and relevant, actively enrolling substudies.
* Participant has a documented clinical diagnosis of PsA with symptom onset at least 6 months prior to the Screening Visit and fulfillment of the Classification Criteria for Psoriatic Arthritis (CASPAR) at Screening Visit.
* Participant has active disease defined as greater than or equal to 3 tender joints (based on 68 joint count) and greater than or equal to 3 swollen joints (based on 66 joint count) at both the Screening Visit and Baseline Visit.
* Participant has active plaque PsO, with at least one psoriatic plaque of \>= 2 cm diameter or nail changes consistent with PsO at Screening Visit.
* Participant must demonstrate intolerance or inadequate response to 1 to 2 targeted therapies (biologic or targeted synthetic disease-modifying antirheumatic drugs) approved for the treatment of PsA

Exclusion Criteria:

* Participants who have had major surgery performed within 12 weeks prior to randomization or plan to have a major surgery during conduct of the study (e.g., aneurysm removal, stomach ligation).
* Participants with the following active, chronic, or recurring infections: Are infected with human immunodeficiency virus (HIV), active hepatitis B virus (HBV) or hepatitis C virus(HCV) infection, active tuberculosis(TB)
* Active skin disease other than psoriasis (PsO) which could interfere with the assessment of PsO.
* History of fibromyalgia, any arthritis with onset prior to age 17 years, or current diagnosis of inflammatory joint disease other than psoriatic arthritis (PsA) (including but not limited to rheumatoid arthritis, gout, overlap connective tissue diseases, scleroderma, polymyositis, dermatomyositis, systemic lupus erythematosus).

Where it's running

• Newport Huntington Medical Group /ID# 272764
  Huntington Beach, California, United States Recruiting
• Highlands Advanced Rheumatology And Arthritis Center - Avon Park /ID# 273085
  Avon Park, Florida, United States Recruiting
• Clinical Research Of West Florida - Phase I Unit /ID# 273198
  Clearwater, Florida, United States Recruiting
• HMD Research LLC /ID# 273086
  Orlando, Florida, United States Recruiting
• West Broward Rheumatology Associates /ID# 272892
  Tamarac, Florida, United States Recruiting
• Clinical Research Of West Florida - Tampa - North Howard Avenue /ID# 273199
  Tampa, Florida, United States Recruiting

Study contacts

• Study coordinator: Abbvie Call Center
• Email: abbvieclinicaltrials@abbvie.com
• Phone: 844-663-3742

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• HLA B Leader in Psoriatic Arthritis

  This study tests whether the HLA B leader gene is more common in people with psoriatic arthritis than in healthy individuals.

  Recruiting Centre Hospitalier Universitaire, Amiens · Amiens, Picardie · NCT07718815

• TaVNS for Psoriatic Arthritis in Adults

  This study tests whether non-invasive taVNS can help reduce disease activity and improve pain and quality of life in adults with psoriatic arthritis.

  Recruiting Marmara University · Istanbul · NCT07653009

• TQH3906 capsules for active psoriatic arthritis in adults

  This trial tests whether TQH3906 capsules help people with active psoriatic arthritis more than a placebo over 12 weeks.

  Recruiting at 36 sites Phase 2 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. · Bozhou, Anhui and 43 other locations · NCT07406035

• Picankibart for people with active psoriatic arthritis

  This trial tests whether subcutaneous picankibart can improve joint and skin symptoms in adults with active psoriatic arthritis who have not had enough benefit from NSAIDs or non-biologic DMARDs.

  Recruiting Phase 2/3 Innovent Biopharmaceutical Technology (Hangzhou) Co., LTD. · Hangzhou, Zhejiang · NCT07295509

• Bimekizumab by IV infusion versus subcutaneous injection for adults with psoriatic arthritis or axial spondyloarthritis

  This trial tests whether bimekizumab given by intravenous (IV) infusion behaves the same in the body as the usual subcutaneous injection in adults with psoriatic arthritis or axial spondyloarthritis.

  Recruiting at 65 sites Phase 1 UCB Pharma · Peoria, Arizona and 64 other locations · NCT07290036

• Continued daily zasocitinib treatment for adults with psoriatic arthritis

  This extension will try daily zasocitinib in adults with psoriatic arthritis who completed a year of earlier treatment to see how well it works and how safe it is over about two years.

  Recruiting at 78 sites Phase 3 Takeda · Tucson, Arizona and 77 other locations · NCT07286058

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.